Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Many congratulations to Professor Sir David Weatherall, who was appointed a Knight Grand Cross of the Order of the British Empire (GBE). This is the highest rank in the Order of the British Empire, an honour only bestowed 16 times since 2000.

David Weatherall is a haematologist and clinical researcher whose research has focused on the genetics of blood disorders affecting haemoglobin, particularly thalassaemia. He was the first to describe thalassaemia outside the Mediterranean and his work has led to the eradication of the disease in some parts of the world. Through his work on thalassaemia, David demonstrated for the first time that a gene deletion could cause a human disease. He developed new methods for analysing haemoglobin and measuring the synthesis of alpha- and beta-haemoglobin chains. This provided the first clear evidence of how thalassaemia arises. In addition, David’s work made possible the detection of thalassaemia early in pregnancy, enabling antenatal diagnosis. His characterisation of the mutations causing thalassaemia led to numerous families being offered genetic counselling.

David has won numerous awards, including the Lasker Prize (which ranks alongside the Nobel Prize for Medicine) and was knighted in 1987. This latest honour also recognises his role in establishing in 1989 the first Institute of Molecular Medicine in the UK (now named the MRC Weatherall Institute of Molecular Medicine in his honour) and in developing the WHO consensus for diagnosing and managing genetic disease, with a global impact.

The announcement was made at the Queen's Birthday Honours earlier in the year, and the investiture ceremony took place at Windsor Castle on the 8th of December.

Similar stories

Project funding for personalised childhood cancer treatments

Funding from the Azaylia Foundation will support the Scientific Advances for Infant Leukaemia (SAIL) programme.

MRC National Mouse Genetics Network Research Clusters Announced

Claus Nerlov and Steve Twigg from the MRC WIMM join the new national network for disease modelling.

From ‘Ew, gross!’ to ‘Wow!’: Scientists bring immunology to the classroom

For British Science Week, members of the MRC WIMM visited a local Oxfordshire primary school for an interactive science day – one of the first of its kind since the start of the pandemic.

Spin-out company Alethiomics launches

The enterprise will focus on developing targeted therapies for a specific family of blood cancers.

Study links the onset of circulation to changes in metabolism affecting blood stem cell development

A new paper published in Cell Reports by the de Bruijn Group indicates that the onset of circulation triggers a metabolic switch associated with the maturation of haematopoietic stem cells.